Aurinia Competitors
| AUPH Stock | USD 8.98 0.03 0.34% |
You can use the Comparative Equity Analysis module to analyze the advantages of investing in your portfolio's related equities across multiple sectors and thematic ideas. Please use the input box below to enter symbols for particular investments you would like to analyze. With the equity comparison module, you can estimate the relative effect of Aurinia Pharmaceuticals competition on your existing holdings.
Aurinia |
Aurinia Pharmaceuticals Competition Correlation Matrix
Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Aurinia Pharmaceuticals and its competitors represents the degree of relationship between the price movements of corresponding stocks. A correlation of about +1.0 implies that the price of Aurinia and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Aurinia Pharmaceuticals does not affect the price movement of the other competitor.
| Click cells to compare fundamentals | Check Volatility | Backtest Portfolio |
High positive correlations
| High negative correlations
|
Risk-Adjusted Indicators
There is a big difference between Aurinia Stock performing well and Aurinia Pharmaceuticals Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Aurinia Pharmaceuticals' multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.| Mean Deviation | Jensen Alpha | Sortino Ratio | Treynor Ratio | Semi Deviation | Expected Shortfall | Potential Upside | Value @Risk | Maximum Drawdown | ||
|---|---|---|---|---|---|---|---|---|---|---|
| VKTX | 3.27 | (0.59) | 0.00 | (0.31) | 0.00 | 5.82 | 39.28 | |||
| AXSM | 1.75 | (0.08) | 0.00 | (0.10) | 0.00 | 4.10 | 13.88 | |||
| MDGL | 2.63 | 0.55 | 0.23 | 0.92 | 2.04 | 5.17 | 30.27 | |||
| IMGN | 5.45 | 3.11 | 1.10 | (0.99) | 1.44 | 8.32 | 141.41 | |||
| MCRB | 4.74 | (0.11) | 0.00 | (0.28) | 0.00 | 10.84 | 28.84 | |||
| EXEL | 1.49 | 0.37 | 0.23 | 0.57 | 1.24 | 2.97 | 16.74 | |||
| TGTX | 3.00 | 0.49 | 0.14 | 0.25 | 3.29 | 7.43 | 24.51 | |||
| BTAI | 4.75 | (0.65) | 0.00 | (0.36) | 0.00 | 9.62 | 29.34 | |||
| SRPT | 1.79 | (0.04) | 0.00 | (0.01) | 0.00 | 3.75 | 18.21 | |||
| HEPA | 3.82 | (0.41) | 0.00 | (1.37) | 0.00 | 8.06 | 35.17 |
Cross Equities Net Income Analysis
Compare Aurinia Pharmaceuticals and related stocks such as Viking Therapeutics, Axsome Therapeutics, and Madrigal Pharmaceuticals Net Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| AXSM | (2.2 M) | (2.2 M) | (2.2 M) | (2.2 M) | (6 M) | (10.6 M) | (27.2 M) | (28.9 M) | (31 M) | (69.7 M) | (105.4 M) | (134.9 M) | (197.8 M) | (239.2 M) | (227.3 M) |
| MDGL | (381 K) | (47.4 M) | (62.8 M) | (90.2 M) | (86.2 M) | (68.7 M) | (26.4 M) | (31.2 M) | (32.8 M) | (72.8 M) | (197.4 M) | (241.1 M) | (299.3 M) | (373.6 M) | (354.9 M) |
| MCRB | (3.1 M) | (3.1 M) | (3.1 M) | (6.1 M) | (16.7 M) | (54.8 M) | (91.6 M) | (89.4 M) | (98.9 M) | (64.2 M) | (86.5 M) | (61.5 M) | (253.8 M) | (113.7 M) | (119.4 M) |
| EXEL | (15.7 M) | 75.7 M | (147.6 M) | (244.8 M) | (268.5 M) | (169.7 M) | (70.2 M) | 154.2 M | 690.1 M | 321 M | 111.8 M | 231.1 M | 182.3 M | 207.8 M | 218.2 M |
| TGTX | (3.6 M) | (853.1 K) | (18.1 M) | (20.5 M) | (55.8 M) | (62.9 M) | (78.3 M) | (118.5 M) | (173.5 M) | (179.3 M) | (285.9 M) | (355.6 M) | (203.8 M) | 12.7 M | 13.3 M |
| BTAI | (636 K) | (636 K) | (636 K) | (636 K) | (636 K) | (636 K) | (2.1 M) | (4.5 M) | (19.3 M) | (32.3 M) | (82 M) | (106.6 M) | (171.8 M) | (179.1 M) | (170.1 M) |
| SRPT | (2.6 M) | (2.3 M) | (121.3 M) | (112 M) | (135.8 M) | (220 M) | (267.3 M) | (50.7 M) | (361.9 M) | (715.1 M) | (554.1 M) | (418.8 M) | (703.5 M) | (536 M) | (509.2 M) |
| HEPA | (843 K) | (843 K) | (843 K) | (5.3 M) | (5.3 M) | (14.3 M) | (17 M) | (14.9 M) | (9.4 M) | (7 M) | (20.4 M) | (32.7 M) | (42.2 M) | (48.9 M) | (46.5 M) |
| PTCT | 30.9 M | 30.9 M | (26.2 M) | (51.6 M) | (93.8 M) | (170.4 M) | (142.1 M) | (79 M) | (128.1 M) | (251.6 M) | (438.2 M) | (523.9 M) | (559 M) | (626.6 M) | (595.3 M) |
| TERN | (17.7 M) | (17.7 M) | (17.7 M) | (17.7 M) | (17.7 M) | (17.7 M) | (17.7 M) | (17.7 M) | (17.7 M) | (68.8 M) | (40.6 M) | (50.2 M) | (60.3 M) | (90.2 M) | (85.7 M) |
| AKRO | (4.6 M) | (4.6 M) | (4.6 M) | (4.6 M) | (4.6 M) | (4.6 M) | (4.6 M) | (4.6 M) | (81.7 M) | (43.8 M) | (79.2 M) | (100.7 M) | (108.9 M) | (151.8 M) | (144.2 M) |
Aurinia Pharmaceuticals and related stocks such as Viking Therapeutics, Axsome Therapeutics, and Madrigal Pharmaceuticals Net Income description
Net income is one of the most important fundamental items in finance. It plays a large role in Aurinia Pharmaceuticals financial statement analysis. It represents the amount of money remaining after all of Aurinia Pharmaceuticals operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.Aurinia Pharmaceuticals Competitive Analysis
The better you understand Aurinia Pharmaceuticals competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Aurinia Pharmaceuticals' competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Aurinia Pharmaceuticals' competition over several years is one of the best ways to analyze its investment potential.| Better Than Average | Worse Than Peers | View Performance Chart |
Aurinia Pharmaceuticals Competition Performance Charts
Five steps to successful analysis of Aurinia Pharmaceuticals Competition
Aurinia Pharmaceuticals' competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by Aurinia Pharmaceuticals in relation to its competition. Aurinia Pharmaceuticals' competition analysis typically involves several steps, including:- Identifying the key players in the market: This involves identifying the major competitors of Aurinia Pharmaceuticals in the market, both direct and indirect, as well as new entrants and disruptive technologies.
- Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
- Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact Aurinia Pharmaceuticals' competitive landscape.
- Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to Aurinia Pharmaceuticals, and developing a strategy to address them.
- Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Complement your Aurinia Pharmaceuticals position
In addition to having Aurinia Pharmaceuticals in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Pharmaceutical Products Thematic Idea Now
Pharmaceutical Products
Fama and French investing themes focus on testing asset pricing under different economic assumptions. The Pharmaceutical Products theme has 61 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Pharmaceutical Products Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Aurinia Pharmaceuticals Correlation with its peers. For more detail on how to invest in Aurinia Stock please use our How to Invest in Aurinia Pharmaceuticals guide.You can also try the Stocks Directory module to find actively traded stocks across global markets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Aurinia Pharmaceuticals. If investors know Aurinia will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Aurinia Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.15) | Revenue Per Share 1.536 | Quarterly Revenue Growth 0.243 | Return On Assets (0.02) | Return On Equity (0.06) |
The market value of Aurinia Pharmaceuticals is measured differently than its book value, which is the value of Aurinia that is recorded on the company's balance sheet. Investors also form their own opinion of Aurinia Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Aurinia Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Aurinia Pharmaceuticals' market value can be influenced by many factors that don't directly affect Aurinia Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Aurinia Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Aurinia Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Aurinia Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.